• Cathepsin B inhibitor CA-074: Technical Guidance & Workflows

  2026-06-14

  Cathepsin B inhibitor CA-074 provides researchers with a selective tool for dissecting cathepsin B’s role in cancer metastasis, neurotoxicity reduction, and immune modulation. It is best suited for in vitro and in vivo studies where high specificity and minimal off-target effects are required. CA-074 should not be used where broad-spectrum inhibition of cysteine proteases is desired.

• Dual-Action Kinase Inhibitors Reshape p38α MAPK Dephosphoryl

  2026-06-13

  The reference study uncovers that specific kinase inhibitors, by stabilizing distinct inactive conformations of p38α MAP kinase, not only block enzymatic activity but also accelerate dephosphorylation by phosphatases. This dual-action mechanism provides a new paradigm for designing highly selective kinase inhibitors with improved potency and specificity in cellular signaling and disease research.

• Lypressin Acetate: Pharmacological Precision, Assay Guidance

  2026-06-12

  Explore the multifaceted pharmacology of Lypressin acetate, with an emphasis on quantitative activity parameters and translational potential. This article provides actionable assay insights and a critical bridge between antidiuretic and emerging antiviral applications.

• Thiamet G: Precision O-GlcNAcase Inhibitor for Translational

  2026-06-12

  Thiamet G, a potent O-GlcNAcase inhibitor from APExBIO, enables researchers to selectively elevate cellular O-GlcNAc levels and dissect post-translational pathways in neurodegeneration, bone anabolism, and oncology. This article delivers actionable workflows, troubleshooting strategies, and protocol enhancements—bridging recent breakthroughs in Wnt-mediated bone formation and tauopathy research.

• GPR30 in Spinal CCK+ Neurons: A Key Modulator of Neuropathic

  2026-06-11

  This study reveals that GPR30, a membrane-bound estrogen receptor, is upregulated in spinal cholecystokinin-positive (CCK+) neurons following nerve injury and is crucial for neuropathic pain signaling. By selectively inhibiting GPR30, the research demonstrates reversal of pain sensitization, identifying GPR30 as a promising therapeutic target for pain modulation.

• Lopinavir (ABT-378): Applied Workflows for HIV and Cross-Pat

  2026-06-11

  Lopinavir (ABT-378) stands out as a potent, serum-resilient HIV protease inhibitor with proven cross-pathogen utility, including MERS-CoV suppression. This article translates high-impact bench findings into actionable protocols, troubleshooting guidance, and innovation strategies for antiviral discovery leveraging APExBIO’s gold-standard Lopinavir.

• Intestinal TM6SF2 Deficiency Drives MASH via the Gut–Liver A

  2026-06-10

  The reference study reveals that intestinal TM6SF2 is a critical modulator of metabolic dysfunction-associated steatohepatitis (MASH), acting through gut barrier integrity and microbiome regulation. By demonstrating a mechanistic link between intestinal lipid handling, lysophosphatidic acid signaling, and hepatic inflammation, the work suggests new targets for therapeutic intervention and disease modeling.

• Deep Learning Detects Cardiotoxicity in iPSC-CM Screening

  2026-06-10

  Grafton et al. present a scalable phenotypic screening platform that combines deep learning with high-content imaging of human iPSC-derived cardiomyocytes to detect drug-induced cardiotoxicity. This approach allows early identification of compounds with cardiotoxic potential, informing safer drug development and improving cardiac electrophysiology research.

• Acifran: Precision Hypolipidemic Agent for Lipid Metabolism

  2026-06-09

  Acifran, a selective HM74A/GPR109A and GPR109B agonist, enables researchers to dissect lipid signaling pathways with structural precision. Recent breakthroughs in cryo-EM structure elucidation empower more informed experimental design and troubleshooting for advanced lipid metabolism and metabolic disorder research.

• EZ Cap™ Human PTEN mRNA (ψUTP): Optimizing Functional mRNA D

  2026-06-09

  Explore how EZ Cap™ Human PTEN mRNA (ψUTP) transforms in vitro transcribed mRNA delivery through enhanced stability, immunoevasion, and translational efficiency. This article uniquely dissects nanoparticle delivery advances and practical assay design to advance cancer research.

• Strategic Src Kinase Inhibition in Translational Oncology: P

  2026-06-08

  This thought-leadership article dissects the mechanistic and translational value of PP 1, a selective Src family tyrosine kinase inhibitor, in cancer and immunology research. Leveraging the latest evidence on metastatic prostate cancer, it offers experimental guidance, protocol parameters, and a forward-looking perspective for translational scientists.

• InstaBlue Protein Stain Solution: Rapid Coomassie Gel Staini

  2026-06-08

  InstaBlue Protein Stain Solution enables ultra-fast, sensitive visualization of protein bands in polyacrylamide gels. This ready-to-use Coomassie Brilliant Blue protein stain minimizes preparation time while offering compatibility with downstream mass spectrometry and preserving protein integrity for biomedical research.

• Chemically Modified tRNA Boosts mRNA Translation Efficiency

  2026-06-07

  This study introduces a tRNA-based approach to enhance the translation capacity of mRNAs, especially those rich in cognate codons. By supplementing or chemically modifying tRNAs, translation output and mRNA stability are significantly improved, offering a practical strategy to overcome bottlenecks in mRNA vaccine and therapeutic development.

• EdU Flow Cytometry Assay Kits (Cy3): Precision DNA Replicati

  2026-06-06

  The EdU Flow Cytometry Assay Kits (Cy3) from APExBIO deliver artifact-free, high-sensitivity DNA synthesis detection for advanced cell proliferation and genotoxicity workflows. This guide details practical experimental enhancements, troubleshooting strategies, and how the kit’s click chemistry advantage empowers robust, multiplexed cell cycle analysis in cancer and drug response research.

• Strategic Protease Inhibition for Translational OXPHOS Resea

  2026-06-05

  A thought-leadership guide for translational scientists: Learn how robust protease inhibition is pivotal for high-fidelity protein studies in advanced cancer metabolism research, including dual-genome OXPHOS targeting strategies. Discover mechanistic insights, protocol parameters, and competitive advantages of EDTA-free solutions like APExBIO's Protease Inhibitor Cocktail (EDTA-Free, 100X in DMSO), with actionable guidance for maximizing protein stability in complex translational workflows.

455 records 15/31 page Previous Next First page 上5页 1112131415 下5页 Last page